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O-001: THE NEW INTERVENTIONAL TECHNIQUE BY PHOTODY-
NAMIC THERAPY USING COMPOSITE-TYPE OPTICAL FIBER-
SCOPE OF 1.0 MM IN DIAMETER FOR PERIPHERAL PARENCHY-
MAL LESION 
Jitsuo Usuda, Taichiro Ishizumi, Yujin Kudo, Hideyuki Furumoto, Hidetoshi Honda, 
Masatoshi Kakihana, Hisashi Saji, Naohiro Kajiwara, Tatsuo Ohira, Norihiko Ikeda  
Surgery, Tokyo Medical University, Shijuku-ku/JAPAN
Background: Ground-glass opacity (GGO) nodules at peripheral parenchyma of the 
lung noted at thin –section computed tomography (CT) scan have shown to have 
a histopathologic relationship with atypical adenomatous hyperplasia (AAH) and 
adenocarcinoma (AIS) which is newly classified by International Association for the 
study of Lung Cancer (IASLC). These preinvasive lesions, which corresponds to type A 
or B adenocarcinoma according to Noguchi classification, are favorable prognosis. We 
hypothesize that those early lung cancers in peripheral parenchyma such as AIS, do not 
need surgical resection may be cured by interventional approach such as Photodynamic 
therapy (PDT). PDT consists of using a tumor specific photosensitizer and laser irradiation 
to induce production of reactive oxygen species in cancer cells. PDT is recommended 
as a treatment option for centrally located early lung cancers (CLELCs), which are 
roentgenographically occult squamous cell carcinomas. Recently, we reported that PDT 
using NPe6, a second generation photosensitizer, exerted a strong antitumor effect against 
cancer lesions > 1.0 cm in diameter, which are assumed to involve extracartilaginous 
invasion and to be unsuitable for treatment with PDT using Photofrin (Clin Cancer Res 
16: 2198-2204, 2010). For peripheral type early lung cancer, it is unable to observe using 
bronchoscopy nor to treat by PDT. Therefore, we have developed a new minimally invasive 
laser device using a 1.0 mm in diameter composite-type optical fiberscope (COF), which 
could transmit laser energy and images for observation in parallel, consisting a laser 
Doppler blood-flow meter. The use of COF technology was previously used in the field of 
atomic energy. It enables the acquisition of an image while simultaneously performing laser 
treatment such as PDT, measuring the blood-flow, estimating the irradiational distance. 
Methods: In this study, we aimed to develop a new endoscopical treatment for peripheral 
parenchymal cancer by NPe6-PDT and a COF. We administered NPe6, 10mg/kg to pigs 
and we observed the peripheral parenchyma through the bronchus using COF. One h after 
the administration of NPe6, we irradiated 664 nm-laser (120 mW, 100J) for normal lesion 
of the peripheral lung using COF. Seven days after PDT, we extracted lungs and examined 
pathologically. Results: We were able to introduce the 1.0 mm COF into pig peripheral 
parenchyma of the lungs and observed feasibly and clearly, and then we performed NPe6-
PDT safely. We measured the blood-flow at the irradiated area by COF during PDT, and we 
observed gradually disappearance of the r the blood-flow. The mean diameter of necrosis 
in normal peripheral lung caused by NPe6-PDT was 16 mm. Conclusion: The 1.0 mm COF 
was a very useful device of NPe6-PDT for peripheral parenchyma of the lung. In the future, 
for non-invasive adenocarcinoma such as AIS, NPe6-PDT using COF will become one 
option of standard treatment and play a important role for the treatment of syncronous or 
metachronouslu multiple primary lung cancer lesions.
Keywords: adenocarcinima in situ, photodynamic therapy, intervention
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O-002: CLINICAL UTILITY OF CT-GUIDED BRONCHOSCOPY 
RADIOFREQUENCY ABLATION AS A NOVEL INTERVENTION 
THERAPY FOR LUNG CANCER
Tomonobu Koizumi1, Tuyoshi Tanabe2, Kenji Tsushima2, Kazunari Tateishi2, Toshiro 
Fukushima2, M Hama2, M Horiuchi2, N Kobayashi2, K Ikegami2, Y Tokoro2, A Ushiki2, 
T Yokoyama2, T Kobayashi2, M Yasuo2, K Urushihata2, H Yamamoto2, M Hanaoka2, K 
Kubo2  
1Comprehensive Cancer Center, Shinshu University School Of Medicine, Matsumoto/
JAPAN, 2Shinshu University School Of Medicine/JAPAN
Background: Radiofrequency ablation (RFA) uses an electromagnetic wave with a 
frequency band and is a new treatment offered as a minimally invasive treatment. 
Since RFA for lung cancer has been more widely used by percutaneous imaging-guided 
therapy, the complications from this method include pain, pneumothorax, hemothorax, 
and pleural effusion. We have developed a new internal cooled electrode for RFA (Japan 
Application No. 2006-88228) suitable for forceps channel bronchoscopy and have 
advanced this method for a clinical application for patients with peripheral type of lung 
cancer. Methods: Method; Patients with pathologically diagnosed with NSCLC, who 
had no lymph node involvement and distant metastases (T1-2N0M0), but not indication 
for surgery because of other complications for example; synchronous multiple nodules, 
advanced age, cardiovascular diseases, poor pulmonary function et al, were enrolled in 
the present study. RFA output power in the generator and temperature were setted to be 
20 - 30 W and 60-70 　, respectively. A peristaltic pump was used to infuse cold water (4　) 
into the internal lumen of the catheter electrode at 50ml/minute. Computed tomography 
(CT) guided bronchoscopy-guided cooled RFA were performed in these patients and 
followed CT. Results: Results; 19 patients, mean age of 73.5 (62-87) yrs were enrolled and 
total 29 RFA were performed. Almost targeted lesions ablated by RFA were changed to be 
scarred or decreased after bronchoscopy-guided cooled RFA. During follow up (median 
32 months, 2.5-73 months) after bronchoscopy-guided cooled RFA, local progression 
occurred in 4 patients and RFA was repeated. The other lesions maintained stable after 
RFA. Four patients died because of progressive disease in one and other causes in three. 
There were no adverse events and complications in the present study. Conclusion: 
Conclusion; Bronchoscopy-guided internal cooled-RFA was safe and feasible procedure 
that could become a potential therapeutic tool in local control in medically inoperable 
patients with stage I non-small cell lung cancer. 
Keywords: Bronchoscopy, RFA
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O-003: CLINICAL ANALYSIS OF UNSUSPECTED N2 DISEASE IN 
RESECTABLE CLINICAL N0 AND N1 NON-SMALL CELL LUNG 
CANCER
Hyeong Ryul Kim1, Yongjik Lee2, Sung Ryong Kim3, Hong Kwan Kim4  
1Department Of Thoracic And Cardiovascular Surgery, Seoul Asan Medical Center, 
Seoul/KOREA, 2Department Of Thoracic And Cardiovascular Surgery, Ulsan University 
Hospital/KOREA, 3Seoul Asan Medical Center/KOREA, 4Department Of Thoracic And 
Cardiovascular Surgery, Samsung Medical Center/KOREA
Background: This study was performed to evaluate the incidence and survival of 
unsuspected pathologic N2 disease and to identify associated risk factors in patients with 
resectable clinical N0 and N1 Non-small cell lung cancer (cN0-1 NSCLC) Methods: Between 
January 2002 and December 2010, 1821 patients with cN0-1 NSCLC underwent surgical 
resection and systematic mediastinal lymph node dissection (MLND). Clinical outcomes 
were analyzed retrospectively. Results: Unsuspected pathologic N2 disease (pN2) was 
identified in 196 patients and it’s prevalence was 10.8% (196/1821). Resections consisted of 160 
lobectomy (81.6%), 20 bilobectomy (10.2%), 12 pneumonectomy (6.2%), 3 sleeve lobectomy 
(1.5%), and 1 segmentectomy (0.5%). Complete resection was not successful in 8 patients 
(4.1%). Perioperative mortality occurred in 3 (1.5%). 177 received adjuvant therapy (90.3%). 
Median follow-up time was 28 (1-101) months. Patients with single and multiple nodal station 
involvement were 121 (66.8%) and 65 (33.2%) respectively. Overall 3 and 5-year survival rate 
(3 and 5 YSR) were 70.5% and 56.1%. Also Median survival time was 76 months. Overall 3 
and 5-year disease free survival rate (3 and 5 DFSR) were 49.2% and 40.3%. Median disease 
free survival time was 35 months. Overall 5-year survival rate in patients with unsuspected 
single station N2 disease compared multiple station N2 disease was 66.6% versus 36.4%, 
respectively (p < 0.01). Age less than 70, Adenocarcinoma histology, clinical N1 disease, and 
tumor size (> 3cm) were independent risk factors for unsuspected N2 disease in multivariate 
analysis. However, Adenocarcinoma histology, clinical N1 disease were the only risk factors 
for unsuspected multiple station N2 disease. Conclusion: The incidence of unsuspected 
N2 disease in patients with cN0-1 NSCLC was similar to previous reports. Overall 5 YSR 
and 5-year DFSR in these patients were favorable, especially for single station N2 disease. 
However, patients with risk factors of unsuspected multiple station N2 disease such as 
adenocarcinoma or clinical N1 disease are considered candidates for aggressive mediastinal 
staging with mediastinoscopy or endobronchial untarsound-guided fine-needle aspiration.
Keywords: Unsuspected N2, clinical N0 and N1, risk factor, multistation N2
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O-004: VALIDATION OF SELECTIVE LYMPH NODE DISSECTION 
FOR CN0 LUNG CANCER
Taichiro Ishizumi, Jitsuo Usuda, Kentaro Fukuda, Wakako Hamanaka, Masaru Hagiwara, 
Hisashi Saji, Masatoshi Kakihana, Naohiro Kajiwara, Tatsuo Ohira, Norihiko Ikeda  
Thoracic Surgery, Tokyo Medical University, Tokyo/JAPAN
Background: As lobe-specific patterns of nodal metastases of lung cancer have become 
recognized, selective lymph node dissection (LND) based on metastatic pathways is 
increasingly common. The aim of this study was to evaluate the effectiveness of selective 
LND for cN0 lung cancer. Methods: We retrospectively evaluated 789 patients with 
previously untreated cN0 lung cancer resected with systematic LND between January 2005 
and March 2011. We evaluated nodal metastatic patterns and frequency according to the 
primary location and pathology. Results: Primary tumor locations were the right upper 
lobe (RUL) in 280, the right middle lobe (RML) in 47, the right lower lobe (RLL) in 178, 
the left upper lobe (LUL) in 163, and the left lower lobe (LLL) in 118. The tumor cell types 
were adenocarcinoma in 611, squamous cell carcinoma in 106, large cell carcinoma in 22, 
adenosquamous cell carcinoma in 7 and others in 43. Among the patients with cN0 lung 
cancer who underwent operation, 8.5% had pN1 (67/789) and 10.5% had pN2 (83/789). In 
the cases of cN0 lung cancer, except cases of adenocarcinoma, the right and left upper lobe 
(RUL and LUL) tumors did not have subcarinal metastases and the right and left lower 
lobe tumors did not have superior mediastinal metastases. On the other hand, 3.1% of 
RUL and 2.0% LUL-superior segment cN0 adenocarcinoma had subcarinal metastases. 
The RUL and LUL-superior segment cN0 adenocarcinomas except 1 patient did not have 
subcarinal metastases when the superior mediastinal nodes were negative, whereas 7.4% 
of left lingular segment adenocarcinomas metastasized to subcarinal nodes even when the 
superior mediastinal nodes were negative. 2.8% of right and 3.0% of left basal segment cN0 
adenocarcinomas had superior mediastinal metastases. The right and left basal segment cN0 
adenocarcinomas did not have superior mediastinal metastases when the subcarinal nodes 
were negative, whereas 3.0% of right S6 and 5.4% of left S6 adenocarcinomas had metastatic 
superior mediastinal nodes even when the subcarinal nodes were negative. All the above-
mentioned patients with lingular segment or right or left S6 adenocarcinoma had hilar 
lymph node metastases. Conclusion: Lobe-specific selective LND is feasible for patients 
with cN0 lung cancer, except cases of adenocarcinoma. In cN0 RUL and LUL-superior 
segment adenocarcinomas, subcarinal dissection may be unnecessary if the superior 
mediastinal node is negative. In cN0 right and left basal segment adenocarcinomas, superior 
mediastinal dissection may be unnecessary if the subcarinal node is negative. On the other 
hand, as left lingular segment adenocarcinomas might metastasize to subcarinal nodes even 
if the superior mediastinal node is negative, and right and left S6 adenocarcinomas might 
metastasize to superior mediastinal nodes even if the subcarinal node is negative, selective 
LND requires confirmation of hilar LN-negative status.
Keywords: Selective lymph node dissection, Clinical N0 lung cancer
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O-005: NIR SPECTROSCOPY IN DIAGNOSIS OF SOLITARY  
PULMONARY NODULES
Jiri Votruba1, Tomas Bruha2  
1Pulmonary, Charles University Hospital Prague, Praha /CZECH REPUBLIC, 2Enex Ltd., 
Praha /CZECH REPUBLIC
Background: Diagnosis of a lung cancer is a challenging process. Recently due to a 
widespread use of a CT, there are more of smaller peripheral lesions being detected. Because 
of an obvious need for a morphological verification, new bronchoscopic methods for biopsy 
of such small peripheral lesions, are needed. We present an easy and cheap method by 
which it is possible to choose the best area for biopsy during bronchoscopy examination. 
The method of question is NIR spectroscopy of penetrating light. We have carried out an 
opened randomized prospective study to discriminate an efficiency of two techniques 
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- transbronchial biopsy under fluoroscopic guidance and a NIR spectroscopy guided 
transbronchial biopsy. Methods: We have designed a simple instrument for measurement of 
a penetrated NIR light through the lung tissue. It consists of two fibers of 1 mm in diameter 
contained in one bundle covered with insulation sleeving. One of the fibers is a detector; 
the other is a source fibre. The indicator fibre is 1,5 cm longer than the source fibre and 
it is separately covered with insulation till its ending. The ending is cut in the angle of 60 
degrees and titan coated in order to facilitate NIR light transmission toward detector fibre. 
The detector fibre is connected to NIR spectroscope and the source fibre to NIR source. 
Measurements of a normal lung tissue at various areas of a lung tissue show characteristic 
peak at 735 nm which is not present during cancer tissue spectroscopy. In cancer tissue 
in addition all detected spectra have got fixed ratio (with minimal dispersion) of two 
standardized transmittance values at two chosen wavelengths (773 and 823 nm)- mirroring 
the source values with its mild modification by tissue autofluorescence. By help of those 
findings we utilized endobronchial measurement of NIR transmittance spectra in attempt to 
improve sensitivity of transbronchial biopsy under fluoroscopic guidance. Patient population 
consisted of 210 patients with CT/PET finding of metabolically active solitary pulmonary 
node 2-5 cm in diameter. Patients have been randomized into the group of fluoroscopic TBB 
and NIR confirmed fluoroscopic TBB.  Results: Method N N positive N negative Sensitivity 
TBB hit rate (%) Fluo+EBUS 106 82 38 0,77 77 NIR+Fluoro 104 90 14 0,87 87 Conclusion: We 
conclude that the use of NIR spectroscopy for ideal biopsy area confirmation has been useful 
in increasing the sensitivity of fluoroscopically guided TBB. Such device or its modifications 
could be easily included for example into the examination by electromagnetic navigation. 
Acknowledgement: This work has originated under the support of financial means from 
the industrial research project of the Ministry of Industry and Trade of the Czech Republic 
– project code FR-TI4/765: “Research and development of technologies and methods for the 
early diagnosis of lung cancer using NIR spectroscopy.
Keywords: transbronchial biopsy, solitary pulmonary nodule, sensitivity, NIR light
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O-006: ECONOMIC EVALUATION OF ROBOTIC-ASSISTED THO-
RACIC SURGERY COMPARED WITH OPEN THORACOTOMY, 
AND VATS
Naohiro Kajiwara, Masatoshi Kakihana, Jitsuo Usuda, Tatsuo Ohira, Norihiko Ikeda  
Surgery, Tokyo Medical University, Tokyo/JAPAN
Background: We evaluated the economical effects for the surgical treatment of thoracic 
disease using the da Vinci® Surgical System (dVS; Intuitive Surgical, Inc., Sunnyvale, 
CA) compared with standard open thoracotomy, and also with conventional video-
assisted thoracoscopic surgery (VATS), and set out to establish a reasonable medical fee 
for robotic-assisted thoracic surgery (RATS) which is not determined yet in our country 
and most other countries of the world. Methods: This study consisted mainly of benign 
and malignant tumors of the mediastinum, chest wall and also lung tumors in the field 
of general thoracic surgery. Usually all perioperative management for RATS, VATS 
and open thoracotomy are the same, such as pre-operation management, anesthesia 
and post-operation management. This study discusses the economic effects of medical 
fees compared with RATS and VATS in the field of general thoracic surgery under the 
new Japanese National Health Insurance System (JNHIS). All surgical procedures were 
performed between March 2010 and June 2012. Results: We calculate the expected price 
according to the prescribed system of the new JNHIS, in which patients make a copayment 
of one third of the total cost and showed that hospitals would suffer a loss if they performed 
only 200 or less the dVS operations per year. Only institutions which have more than 300 
cases per year of the dVS operations show good economic performance for general thoracic 
surgical diseases. This figure agrees with the projections made for prostatectomies, for 
which the system received government approval in 2012. Conclusion: It is necessary to 
perform the dVS operations at least 300 times a year at one institution to achieve robotic 
surgical management that does not cause deficit income and expenditure in the current the 
dVS pricing. However the procedures would not have to be all the same type, e.g. that could 
be 200 prostatic and 100 thoracic procedures. Furthermore, reduced price revision of the 
dVS operation by the Japanese Ministry of Health, Labor and Welfare, or lowering of the 
dVS price by Intuitive Surgical Inc. is hoped for in the near future with the development 
of competing technologies. The present study should help guide the correct economic 
evaluation for robotic procedures in many countries in the coming years.
Keywords: thoracic surgery, Robotic surgery
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O-007: LOBECTOMY IN ELDERLY PATIENTS WITH NON-SMALL 
CELL LUNG CANCER: COMPARATIVE STUDY OF THORACO-
SCOPIC SURGERY VS. THORACOTOMY IN TERMS OF PERIOP-
ERATIVE COMPLICATION REGARDING INVASIVENESS AND 
RESULTS OF SURGERY
Hideyuki Furumoto, Yoshihisa Shimada, Masaru Hagiwara, Masatoshi Kakihana, 
Hisashi Saji, Hidetoshi Honda, Masaharu Nomura, Jitsuo Usuda, Naohiro Kajiwara, 
Tatsuo Ohira, Norihiko Ikeda  
Surgery I, Tokyo Medical University, Tokyo/JAPAN
Background: As the general population ages, thoracic surgeons will increasingly be 
presented with the task of treating elderly patients with resectable non-small cell lung 
cancer (NSCLC). Pulmonary resection in elderly patients requires special consideration 
because of reduced organ function and concomitant morbidities. Emerging experience 
suggests that a video-assisted thoracic surgery (VATS) for NSCLC patients with early 
lung cancer may parallel conventional thoracotomy in terms of oncologic efﬁcacy, while 
decreasing perioperative morbidity. The objective of this study is to assess the perioperative 
complications and performance of surgery of patients ≥ 75 years with NSCLC who 
underwent thoracoscopic lobectomy, compared to those who underwent open thoracotomy. 
Methods: From September 2009 through March 2012, a total of 471 patients underwent 
pulmonary lobar resection with lymph node dissection for lung cancer at our hospital. Of 
these, 107 patients (22.7%) ≥ 75 years satisfied the enrollment criteria of this study. Clinical 
characteristics were retrieved from available clinical records. We performed univariate and 
multivariate analyses to determine the independent predictive factors for postoperative 
complications, and p-values of less than 0.05 were considered to indicate a statistically 
significant difference. Results: Of the 107 patients ≥ 75 years who underwent lobectomy, 
open thoracotomy (open) was performed in 69 (64.5%), and VATS approach was 38 (35.5%). 
There were 2 conversions due to vascular injury (5.6%). The mean age was 77.6 ± 0.3 years for 
the open thoracotomy group, and 79.6 ± 0.5 years for VATS group (p = 0.002). Pathological 
staging showed the open/ VATS groups consisted of 39 / 31 in stage I, 17/ 1 in stage II, and 
13/ 5 in stage III, respectively(stage I vs. stage II-III; p = 0.01). There were 83 patients (77.6%) 
who had preoperative comorbidities in both group, including (chronic pulmonary disease; 
17:19, diabetes; 15:5, and coronary artery disease; 6:1 in the open: VATS groups, respectively 
(p = NS). Perioperative data of the VATS groups showed lower intraoperative blood loss 
(p<0.001), shorter operative time: (p=0.009), lower post/ preoperative serum creatine kinase 
ratio (p = 0.001), lower chest drain discharge in the first 2 days after operation (p < 0.001), 
and shorter period of chest tube replacement (p = 0.012), compared to the open group. There 
were 25 (23.4%) patients with postoperative complications, including 3 major complications 
(empyema in the open group, and postoperative bleeding in the VATS group, respectively). 
On multivariate analysis, VATS procedure was shown to be independently signiﬁcant 
negative predictive factor for postoperative complications: (hazard ratio [HR], 0.08; p = 
0.03) Conclusion: Compared with open thoracotomy, VATS lobectomy for elderly patients 
appears to cause less morbidity. 
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O-008: VIDEO-ASSISTED THORACOSCOPIC LOBECTOMY FOR 
THE TREATMENT OF NON-SMALL CELL LUNG CANCER
Jae Hyun Jeon, Chang Hyun Kang, Yong Won Seong, Hye Seon Kim, In Kyu Park, Young 
T. Kim  
Thoracic And Cardiovascular Surgery, Seul National University Hospital, Seoul/KOREA
Background: To review our experience with video-assisted thoracoscopic surgery (VATS) 
lobectomy in non-small cell lung cancer (NSCLC) patients with respect to morbidity, 
mortality, and long-term outcomes. Methods: VATS lobectomies for NSCLC were 
performed in 738 patients between 2005 and 2012, consecutively. Clinical data for these 
patients were collected from medical records and analyzed retrospectively. Results: There 
were 371 males (50.2%) and mean age was 62.7 ± 10.0 years. Patients were discharged a 
median of 5 days after their surgery. The most common histologic type of lung cancer was 
adenocarcinoma (75.6%). Pathologic stage distributions were as follows: stage IA (50.9%), 
IB (30.0%), IIA (7.9%), IIB (1.8%), IIIA (8.1%), IV (1.3%). The mean tumor size was 2.4 
± 1.2 cm in greatest dimension and mean number of dissected lymph nodes was 24.8 ± 
10.1. The hospital mortality rate was 0.8% (6 patients). Five of them died of postoperative 
pneumonia, and one died of acute respiratory distress syndrome. One hundred thirty 
patients (17.6%) experienced postoperative complications. Common complications were as 
follows: postoperative arrhythmia (5.8%), prolonged air leakage more than 7 days (4.4%), 
vocal cord paralysis (1.6%), chylothorax (1.4%), reoperation (1.4%). Median follow-up for 
all 738 patients was 14.9 months (range, 1 to 86 months). During the follow-up period, 16 
deaths and 81 recurrences were observed. The overall 3-year survival was 95.5% (95.7% in 
stage I, 85.0% in stage II, and 85.0% in stage III). The 3-year disease-free survival was 79.0% 
(83.3% in stage I, 70.5% in stage II, and 47.5% in stage III). 
Figure 1. Overall survival curves of 738 NSCLC patients who were performed VATS lobectomy. 
Figure 2. Disease free survival curves of 738 NSCLC patients who were performed VATS lobectomy. 
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Conclusion: VATS lobectomy in lung cancer could be performed safely with good early 
postoperative outcomes and excellent long-term survival.
Keywords: non-small cell lung cancer, Surgery, Video-assisted thoracoscopic, lobectomy
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O-009: MOLECULAR MECHANISMS OF CIGARETTE SMOKE-
INDUCED PROLIFERATION OF HUMAN LUNG CELLS AND ITS 
PREVENTION.
Neekkan Dey, Shinjini Ganguly, Indu B. Chatterjee, Dhrubajyoti Chattopadhyay  
Department Of Biotechnology, University Of Calcutta, Kolkata/INDIA
Background: Lung cancer is the leading cause of cancer-deaths throughout the World. 
The mechanisms of initiation of lung cancer involve hyperplasia (proliferation). 
Although cigarette smoking is the strongest risk factor for developing lung cancer, 
the mechanisms of smoke-related cell proliferation are poorly understood. This is 
particularly because cigarette smoke is a complex mixture of about 4000 compounds 
and to date identification of specific chemical(s) that causes proliferation of lung 
cells has not been possible. Methods: Cell proliferation was assessed using “In Situ 
Cell Proliferation Kit, FLUOS” (Roche Applied Science, Germany). Cytotoxicity was 
evaluated by the MTT assay. Cell cycle analysis was performed by propidium iodide (PI) 
staining followed by flow-cytometry. Apoptosis was assessed by AnnexinV- PI staining 
followed by flow-cytometry. Reactive Oxygen Species (ROS) production was detected 
by 2’, 7’-dichlorodihydrofluorescein diacetate (H2DCFDA) fluorescence using confocal 
laser scanning microscope. DNA double strand break was detected using “OxiSelect 
DNA Double Strand Break (DSB) Staining Kit” (CELL BIOLABS, INC.). Results: Here 
we show that p-benzoquinone (p-BQ), derived from p-benzosemiquinone (p-BSQ) 
of cigarette smoke (CS) is a major risk factor responsible for proliferation of lung cells 
(A549). p-BSQ is present in large amounts in all commercial cigarettes examined. Under 
the experimental conditions, benzo[a]pyrene or nitrosamines (e.g. NNK and NNN) does 
not induce proliferation. Using MTT assay, flow-cytometric analysis after AnnexinV-
PI staining, cell cycle analysis and BrdU-incorporation assay we have observed that 
p-BQ has a biphasic-nature. While low concentrations of p-BQ mimic CS-solution 
for proliferation of cells, high concentrations cause cytotoxicity, oxidative stress 
and apoptosis. The oxidative stress has been evidenced by the formation of ROS and 
apoptosis by the AnnexinV-PI assay, phosphorylation of p53 and activation (cleavage) of 
caspase 3. No such oxidative stress or apoptosis was observed with low concentration of 
CS/p-BQ. Coimmunoprecipitation and immunoblot experiments indicate that p-BQ-
induced proliferation is mediated via aberrant phosphorylation of EGFR that lacks c-Cbl 
mediated ubiquitination and degradation. This results in prolonged EGFR signaling 
leading to persistent activation of Ras (potent oncoprotein that play a major role in lung 
cancer), the downstream survival and proliferative signaling molecules Akt and ERK1/2, 
as well as the transcription factors c-Myc and c-Fos. In addition, repeated p-BQ exposure 
generate high levels of DNA double strand breaks and induce cultured lung cells to evade 
the cell cycle checkpoints, that may cause mutations of different proto-oncogenes and 
tumor suppressor genes that ultimately lead to cancer. Both anti-p-BQ antibody and 
vitamin C (a strong reductant of p-BQ) prevent CS/p-BQ-induced activation of EGFR 
and proliferation of lung cells. Conclusion: Despite major advances in the treatment 
and management of lung cancer, most patients eventually die. Consequently, newer 
approaches such as chemoprevention(s) are necessary in the battle against lung cancer. 
We consider that prevention of CS-induced proliferation of lung cells by vitamin C and/
or anti-p-BQ antibody may provide a novel intervention for preventing initiation of CS-
induced lung cancer.
Keywords: LUNG CANCER, cigarette smoke, p-benzoquinone (p-BQ), anti-p-BQ 
antibody
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O-010: THE RISK OF TOBACCO-SPECIFIC LUNG CARCINOGEN 
AMONG NON-SMOKING RESTAURANT AND BAR WORKERS IN 
NIGERIA
Emmanuel Odiase  
Epidemiology, University Of Ibadan/Smokefree Foundation, Ibadan/NIGERIA
Background: To say that tobacco smoking causes lung cancer is an understatement. 
Smoking causes numerous cancers but lung cancer is the most frequent. The alarming 
issue at hand is that smoking may cause lung cancer among non smokers in work places 
or elsewhere. Goals: We studied the effect of environmental tobacco smoke (ETS) on 
tobacco-specific lung carcinogen risk 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNAL) among non-smoking bar and restaurant workers. Methods: We examined 
about 200 restaurant and bar non-smoking staff in four geo-political locations in 
Nigeria-Lagos, Kano, Port-Harcourt and Abuja from 2005-2009. Second-hand smoke 
levels were compared with results from these participants who were exposed to it. We 
took note of how long each person had worked in these bars or restaurants and the 
amount of Environmental Tobacco Smoke (ETS) each of them had been exposed to. 
Results: Participants exposed to workplace second-hand smoke were more likely to 
have a detectable level of NNAL (P=0.005) and higher mean levels of NNAL (P <0 .001) 
compared with non-exposed participants. Increased levels of NNAL were also associated 
with hours of a single workplace exposure (P=0.005). Conclusion: Non-smoking 
employees left unprotected from workplace second-hand smoke exposure had elevated 
levels of a tobacco-specific carcinogen in their bodies. All workers including bar and 
restaurant workers should be protected from indoor workplace exposure to cancer-
causing second-hand smoke.
Keywords: smoking, risk, lung carcinogen, tobacco-specific
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O-011: THE INFLUENCE OF SMOKING INTENSITY ON THE 
CLINICOPATHOLOGIC FEATURES AND SURVIVAL OF PATIENTS 
WITH SURGICALLY TREATED NON-SMALL CELL LUNG CANCER
Seong Yong Park1, Jin Gu Lee1, Changyoung Lee2, Mi Kyung Bae3, Lee Seokkee4, Dae Joon 
Kim1, Kyung Young Chung1  
1Department Of Thoracic And Cardiovascular Surgery, Yonsei University, College Of 
Medicine, Seoul/KOREA, 2Department Of Thoracic & Cardiovascular Surgery, Yonsei 
University College Of Medicine/KOREA, 3Department Of Thoracic And Cardiovascular 
Surgery, Yonsei University Health System, Yonsei University College Of Medicine, Seoul/
KOREA, 4The Department Of Thoracic And Cardiovascular Surgery, Yonsei University 
College Of Medicine, Seoul/KOREA
Background: Smoking is a well-known risk carcinogen of lung cancer and cigarette 
smoking has also been reported to be a negative prognostic factor for lung cancer 
patients. However, whether cigarette smoking affects the biological behavior of lung 
cancer remains uncertain. This study aimed to investigate the influences of smoking 
intensity on clinicopathologic characteristics and survival of non-small cell lung cancer 
(NSCLC). Methods: We retrospectively reviewed the medical records of 2,238 
consecutive patients who underwent surgical resection for NSCLC between 1990 and 
2010. Smoking intensity was defined as pack-years (PY). The patients were divided into 3 
groups, by median value of smoking: nonsmokers, light smokers (less than 40 PY) and 
heavy smokers (more than 40 PY). Results: There were 1,629 (72.8%) male patients and 
mean age was 61.71 ± 13.17 years. Adenocarcinoma was reported in 1,058 (47.3%) 
patients. The median follow-up period was 30.7 months (range: 0.0 - 261.7 months). The 
5-year overall survival for nonsmokers, light smokers and heavy smokers was 60.1%, 
51.6% and 43.2%, respectively (p<0.001). In subset analysis by histology, the 5-year 
overall survival differed according to smoking intensity in adenocarcinoma patients 
(64.2% in nonsmokers, 51.9% in light smokers and 39.4% in heavy smokers, p<0.001), but 
there was no difference in the non-adenocarcinoma patients. In adenocarcinoma 
patients, the 5-year overall survival also differed according to smoking intensity at each 
stage. The incidences of vascular invasion (p=0.028), pleural invasion (p=0.013) and poor 
differentiation (p<0.001) were higher in heavy smokers than in light smokers or 
nonsmokers. Tumor size was also larger in heavy smokers compared to the other groups 
(p<0.001). After adjusting the sex, stage, lung function, type of operation, neoadjuvant 
therapy and adjuvant therapy, smoking intensity was an adverse risk factor in surgically 
treated adenocarcinoma patients in terms of overall survival (hazard ratio=1.008, 
p=0.028) and disease-free survival (hazard ratio=1.005, p=0.019). 
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Conclusion: Smoking intensity was an adverse prognostic factor after surgical 
resection of adenocarcinoma and heavy smoking was correlated with poor pathologic 
characteristics of adenocarcinoma. The relationship between heavy smoking and poor 
pathologic characteristics may explain the poor survival of heavy smokers.
Keywords: smoking, survival, lung cancer surgery
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O-012: EXPRESSION OF CAP1 IN TUMOR TISSUES AND ITS RELA-
TIONSHIP TO METASTASIS AND PROGNOSIS OF LUNG CANCER
Min Tan1, Xiao Lian Song2, Changhui Wang2  
1Shangai Tenth People’S Hospital, Shanghai/CHINA, 2Respiratory, The Shanghai 10Th 
People’S Hospital, Shanghai/CHINA
Background: Lung cancer ranks top incidence of malignant tumors in the world. The 
5-year survival rate of lung cancer is 15%. Metastasis is the main cause of relapse and 
death. Early detection and intervention of metastasis is the key in the diagnosis and 
management of lung cancer. Recently some studies reported that cytoskeleton may 
associate with metastasis of lung cancer. Cyclase-associated protein 1 is an important 
protein to maintain the stability of cytoskeleton. Several studies reported that CAP1 
could promote cell to form parapodium. Whether lung cancer cells expressed higher 
level of CAP1 may get higher speed of migration to promote metastasis? In our study 
we will explore the correlation and possible mechanism between CAP1 and metastasis 
of lung cancer by molecular biological and cell biological experiments. Methods: 1)
Collected the lung cancer and non-neoplastic lung tissues which were obtained from 
patients who underwent surgical resection. RNA was extracted from these samples. Then 
we determined the expression of CAP1 in mRNA level by RT-PCR. 
2) Protein was extracted from the samples above. The expression of CAP1 in protein 
level was determined by Western-blot. 3) Eighty two paraffin-embedded lung cancer 
sections were collected from 2007-2008.The expression level of CAP1 was determined 
by Immunohistochemical Analysis. The correlation between expression level of CAP1 
and metastasis as well as prognosis of lung cancer was analyzed by statistical method. 
Results: 1)The result of real-time quantitative RT-PCR showed that the CAP1-mRNA 
was overexpressed compared with normal lung cancer. The lung cancer tissues of 
metastasis in following up expressed higher level of CAP1(1.249±0.411) compared with 
those of no metastasis (0.476±0.217,P=0.16). 2)We raised a monoclonal antibody against 
CAP1, which showed a single 53-kDa band of strong intensity in lung cancer tissues 
but only a weak band in the non-cancerous lung tissues in Western blot analysis. And 
the intensity of the band is stronger in the lung cancer of metastasis compared with 
that of non-metastasis. 3) The expression of CAP1 in all 82 cases of lung cancer was 
recognized by immunohistochemical analysis. The ratio of CAP1-positive tumor cells in 
clinical specimens was correlated with the presence of metastasis (especially lymph node 
metastasis) and overexpression of CAP1 is an independent risk factor in metastasis of 
lung cancer. Kaplan–Meier survival analysis demonstrated that the prognosis was poor 
in lung cancer patients with a high level of CAP1. Conclusion: Our findings showed that 
CAP1 was up-regulated in lung cancer when compared with non-cancerous lung tissues. 
CAP1 overexpression correlated with metastasis and poor prognosis of lung cancer.
Keywords: CAP1, LUNG CANCER, metastasis, Prognosis
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O-013: PROGNOSTIC IMPLICATIONS OF VASCULAR INVASION 
DIFFER BETWEEN LUNG ADENOCARCINOMA AND SQUAMOUS 
CELL CARCINOMA
Shingo Usui, Yuko Minami, Masayuki Noguchi  
Department Of Pathology, Faculty Of Medicine, University Of Tsukuba, Tsukuba-shi, 
Ibaraki/JAPAN
Background: Vascular invasion (VI) has been accepted as a universally important 
prognostic factor of lung carcinoma. However, the significance of VI in various 
histological subtypes has been unclear. Methods: A total of 336 patients who had 
undergone surgery at the University of Tsukuba Hospital between January 2000 and 
December 2010 were reviewed retrospectively. Among them, 81 were diagnosed as 
having peripheral-type squamous cell carcinoma, and 255 as having adenocarcinoma. 
The largest cut surface was stained with hematoxylin-eosin and elastica-Van-Gieson. 
D2-40 was also stained using immunohistochemistry. Cancer-free survival analysis was 
performed using the Kaplan-Meier method, and the significances of differences between 
survival curves was assessed by log-rank test. To examine associations with 
clinicopathological factors, chi-squared test was used for categorical variables, and 
multivariate analysis was performed using the logistic regression model.  Results: Five-
year survival rates for VI-positive and -negative cases were 38.4% and 76.3%, 
respectively, and the difference between them was significant (p<0.0001). Although the 
difference in cancer-free survival between VI-positive and -negative cases was 
statistically significant for adenocarcinoma (p<0.0001), it was not significant for 
squamous cell carcinoma (p=0.086). In adenocarcinoma, pathological T and VI were 
identified as independent prognostic factors by multivariate analysis, and its hazard ratio 
for patients with pT2 or more and VI positivity was 5.49 and 2.67 times higher than that 
for patients with pT1 and VI negativity, respectively. The survival curves of patients with 
various subtypes of adenocarcinoma were then compared. The five-year survival rates 
was for the lepidic, solid, papillary and acinar subtypes were 83.3%, 55.9%, 33.4%, and 
27.2%, respectively, and the difference between the survival curves for VI-positive and 
-negative cases was most significant for the lepidic subtype (p<0.0001), whereas that for 
the solid subtype was not significant (p=0.58). Cases of peripheral squamous cell 
carcinoma were divided into two groups on the basis of the diameter of vessels invaded 
by cancer: large vessel invasion (LVI; 1000 μm or more) and small vessel invasion (SVI; 
less than 1000 μm). Although there was no difference in the five-year survival rate 
between the LVI and SVI groups, the LVI group showed a significantly higher incidence 
of macroscopic cavity formation and necrotic cavity formation.  
Fig. The 
survival 
curves 
of adenocarcinoma, peripheral squamous cell carcinoma and various subtypes of 
adenocarcinoma between VI positive (red line) and negative cases (green line). 
Conclusion: We have confirmed that VI is a useful prognostic indicator in 
adenocarcinoma, but not in squamous cell carcinoma. Furthermore, it was interesting 
that VI was an independent prognostic factor in lepidic, acinar, and papillary-
predominant adenocarcinoma, but not in solid-predominant adenocarcinoma. In 
squamous cell carcinoma, large vascular invasion (LVI) was significantly associated with 
macroscopic cavity formation. 
Keywords: Vascular invasion, histological subtype, Prognostic factor
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O-014: COMPARISON OF LONG TERM SURVIVAL AFTER  
BILOBECTOMY AND LOBECTOMY
Lee Seokkee1, Kyung Young Chung1, Dae Joon Kim1, Jin Gu Lee1, Changyoung Lee2, Mi 
Kyung Bae2, Sung Young Park3  
1Department Of Thoracic And Cardiovascular Surgery, Yonsei University, College Of 
Medicine, Seoul/KOREA, 2The Department Of Thoracic And Cardiovascular Surgery, 
Yonsei University College Of Medicine, Seoul/KOREA, 3Department Of Thoracic & 
Cardiovascular Surgery, Yonsei University College Of Medicine/KOREA
Background: The purpose of this study was to evaluate the long term results of 
bilobectomy performed for non-small cell lung cancer(NSCLC). Methods: A 
retrospective review of 157 patients who underwent bilobectomy (group A) for NSCLC 
between January 1992 and July 2009 was undertaken. We compared with data for 418 
patients who underwent right side lobectomy (group B) for NSCLC during same period. 
Results: Group A had more squamous histology, advanced stage, and more larger sized 
tumor compared with group B. Thirty-day mortality rate was higher in group A than 
group B (4.5% vs 2.2%, p=0.156) and morbidity was higher in group A (17.8% vs 12.2%, 
p=0.080). Recurrence rate was lower in Group B than Group A (29.2% vs 38.2%, p=0.38). 
Overall 5-year survival was higher in group B than in group A (55.5% vs 73.7%); but 
adjusted 5-year survival was not significant difference in both groups (group A vs group 
B = 72.1% vs 71.9%, p=0.724). Covariates was age, FEV1(%), tumor size, recurrence of 
tumor, and pathologic stage.
 
Conclusion: Bilobectomy is another type of resection for non-small cell lung cancer. But 
bilobectomy is considered higher mortality and morbidity than lobectomy. We analyzed 
the long term result of bilobectomy and compared with lobectomy. The overall survival 
was comparable in both procedures when considering other factors.
Keywords: non-small cell lung cancer, bilobectomy, lobectomy
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O-015: SURGICAL RESULTS OF SYNCHRONOUS MULTIPLE  
PRIMARY LUNG CANCERS WITHOUT MEDIASTINAL LYMPH 
NODE METASTASIS
Yu-chao Yu1, Chien Sheng Huang2, Po-kuei Hsu1, Teh-ying Chou2, Chih-cheng Heish1, 
Yu-chung Wu2, Biing-shiung Huang2, Wen-hu Hsu2  
1Division Of Thoracic Surgery, Department Of Surgery, Taipie Veterans Genral Hospital, 
Taipei/TAIWAN, 2 Taipei Veterans General Hospital/TAIWAN
Background: Preoperatively distinguish independent synchronous multiple primary 
lung cancers (SMPLCs) from metastases are crucial but still challenging. The primary 
objective of present study was to evaluate the feasibility of surgical approach of these 
patients. In secondary objective, we also compared the survivals between SMPLCs 
and matched-stage of solitary primary lung cancers (SPLCs) after surgical treatments 
during the same period. Methods: Medical records were retrospectively reviewed. The 
patients met the modified Martini and Melamed criteria between 2001 and 2010 were 
enrolled. Patients at the same period received surgical intervention for SPLC without 
mediastinal lymph node involvement were also enrolled as a control group. Results: 
Between Jun 2001 and Dec 2011, 1956 patients received pulmonary resection for lung 
cancer in a tertiary referral center. One hundred and eleven patients met the criteria 
of modified Martini and Melamed about the SMPLCs and 14 patients were excluded 
due to incomplete resection, receiving preoperative neoadjuvant chemotherapy, lost 
follow-up, diagnosed with small cell carcinoma, N2 lesion, metachronous lesions and the 
possibility of metastatic lesions. The location of the tumors was unilateral in 85 patients 
and bilateral in 12 patients. There was no surgical mortality. The median follow-up time 
was 38.8 months. The 3-year and 5-year overall survival rate was 83.1% and 69.6%. In 
univariate analysis, male gender (p=.020; HR: 2.475), smokers (p=.025; HR: 2.297) and 
the largest tumor size great than 3 cm (T1 group) (p=.014; HR: 3.035) had significant 
poor survivals. After adjustment, only the largest tumor size (p=.018; HR: 3.199) 
identified as an independent survival predictor. In addition, there was no significant 
difference in overall survivals between the matched-stage of SMPLCs and SPLC without 
mediastinal lymph node involvement. Subgroup analysis in the multiple synchronous 
adenocarcinoma (N=78) demonstrated that there was no significant difference between 
similar and different comprehensive histological subtyping in overall survivals (61.3 
% vs. 68.8%, p=.474). Conclusion: The surgical results of N2-negative SMPLCs were 
acceptable even with similar histological subtyping and compatible with SPLCs, instead 
of T4 or M1 in current TNM classification system. Preoperative the largest tumor size 
was the only independent prognostic factors for SMPLCs with surgical intervention. 
Keyword: Synchronous Multiple Primary Lung Cancers
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O-016: RESIDUAL FDG-AVIDITY AFTER DEFINITIVE RADIATION 
THERAPY FOR NON-SMALL CELL LUNG CANCER CORRELATES 
WITH LOCAL FAILURE-FREE SURVIVAL AND OVERALL  
SURVIVAL
Andreas Rimner1, Leonard Ong2, Rafael Yah1, Nicholas Bergfeld1, Amanda Mclane1, 
Abraham J. Wu1, Kenneth E. Rosenzweig3, Joseph O. Deasy4, Ellen Yorke4, John Humm4, 
Mark Dunphy2, Daphna Y. Gelblum1  
1Department Of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New 
York/NY/UNITED STATES OF AMERICA, 2Department Of Nuclear Medicine, 
Memorial Sloan-Kettering Cancer Center, New York/NY/UNITED STATES OF 
AMERICA, 3Department Of Radiation Oncology, Mount Sinai Medical Center, New 
York/NY/UNITED STATES OF AMERICA, 4Department Of Medical Physics, Memorial 
Sloan-Kettering Cancer Center, New York/NY/UNITED STATES OF AMERICA
Background: Locoregional control after definitive radiation therapy (RT) for non-
small cell lung cancer (NSCLC) remains suboptimal. We investigated the ability of 
post-treatment PET scanning within 6 months from RT completion to identify areas 
of residual disease and to predict for locoregional failure and survival. Methods: We 
retrospectively identified all patients with NSCLC treated between 11/2001 and 02/2011 
who had a PET scan within 6 months from the end of definitive RT. All PET scans were 
analyzed in a blinded fashion for maximum standardized uptake value (SUVmax), 
average standardized uptake value (SUVaverage), metabolic tumor volume (MTV) based 
on a threshold of 42% of the SUVmax, and total lesion glycolysis (TLG), defined as the 
product of the SUVaverage and the MTV of the primary tumor. Kaplan-Meier analysis 
was performed to estimate survival rates, and PET parameters were correlated with local 
failure of the primary tumor and overall survival rates using the log-rank test. Results: 
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We identified 86 patients that met our inclusion criteria. Median follow-up in alive 
patients was 44 months. Eighty-five percent of patients had stage III disease, and 94% 
received sequential or concurrent chemotherapy. The median RT dose was 6400cGy in 32 
fractions (range 4600cGy to 8400cGy). The median time from the end of RT to PET scan 
was 3.4 months. The residual median SUVmax, SUV average, MTV and TLG were 4.7, 
2.7, 19.3 and 58822, respectively. Local failure-free survival (LFFS) and overall survival 
(OS) at 3 years were 39% and 37%, respectively. Using the median values as a cut-off, 
lower SUVmax (p=0.003), SUVaverage (p=0.002) and TLG (p=0.02) were significantly 
correlated with better LFFS, but MTV was not. Lower SUV max was associated with 
improved OS (p=0.03), with a trend of SUV average and TLG towards improved OS. 
MTV was not predictive of OS. The only dosimetric factor associated with improved 
LFFS and OS was RT dose ≥6000cGy. Tumor size, stage, histology, KPS or concurrent vs 
sequential chemotherapy were not significantly associated with LFFS or OS. Conclusion: 
Residual SUVmax, SUV average, and TLG of the primary tumor within 6 months after 
definitive RT appear to be associated with residual disease and high local failure rates, 
while MTV is not a good surrogate for LFFS and OS.
Keywords: PET, total lesion glycolysis, non-small cell lung cancer, radiation therapy
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O-018: A MOLECULAR EPIDEMIOLOGY STUDY IN ASIAN  
PATIENTS WITH ADVANCED NSCLC OF ADENOCARCINOMA 
HISTOLOGY TO ASSESS EGFR MUTATION STATUS: PIONEER 
STUDY (THAILAND DATA)
Sumitra Thongprasert1, Sarayut L. Geater2, Vichien Srimuninnimit3, Virote Sriuranpong4  
1Chiang Mai University, Chiang Mai/THAILAND, 2Prince Of Songkla, Hat Yai/
THAILAND, 3Siriraj Hospital, Bangkok/THAILAND, 4, Chulalongkorn University, 
Bangkok/THAILAND
Background: Lung cancer is the leading cause of death in Thai population and its 
incidence is increasing every year. EGFR mutation is an important biomarker to predict 
effectiveness of EGFR-TKI drug as patients with mutation positive have better response 
than ones without. Previously published data revealed that EGFR mutations were 
frequently found in Asian female NSCLC patients with adenocarcinoma histology or never 
smokers. Thus, this study aims to examine the mutation status and its correlation with 
demographic data and smoking history in Thai population to provide useful information 
to clinicians for making treatment decision. Methods: Thai NSCLC patients who have 
histologically or cytologically confirmed advanced (stage IIIb/IV) of adenocarcinoma 
histology and able to provide cancer tissue or cytology sample and treatment naïve were 
screened. Informed consent was obtained from each patient before any study procedures 
were performed. Demographic data, smoking history and disease stage were collected. All 
available tissue or cytology samples were tested by SCORPION ARMS method. Results: 
119 Thai ethnic patients from 4 participating sites were enrolled to the study. 67 (56.3%) 
were males and 52 (43.7%) were females. The mean (SD) age of the patients was 60.3 yrs 
(12.3) with a minimum of 19 yrs and maximum of 85 yrs. The total number of patients 
who never smoked was 43 (36.1%), ex-smokers was 52 (43.7%), occasional smokers was 6 
(5%) and regular smokers was 18 (15.1%). Among patients with smoking history (76), mean 
(SD) pack-years was 27.7 (38.7). 97 out of 119 (81.5%) patients had a metastatic disease at 
original diagnosis. Out of 117 patients with successful EGFR mutation test, EGFR mutation 
status was found to be positive in 63 (53.8%) and negative in 54 (46.2%). Out of 63 patients 
with positive status, 33 patients (63.5%) were female. Among all clinical factors only 
smoking history was significantly correlated with EGFR mutation status. Never-smokers 
significantly correlated with positive EGFR test (p=0.03). Conclusion: Prevalence of 
EGFR mutation in Thai NSCLC patients was 53.8%. Smoking history was reported as an 
only correlated factor of positive EGFR mutation test in this study. Other clinical factors 
(e.g. gender) reported in previous studies to have strong correlation with EGFR mutation 
status could not be demonstrated here. The discrepancy might be due to limited number of 
subjects. A larger sample size is warranted for result confirmation.
Keywords: NSCLC, EGFR mutation, THAILAND
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O-019: NOVEL MOLECULAR PROPERTIES IN ACQUIRING RESIS-
TANCE TO EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS
Kazuhiko Shien1, Shinichi Toyooka1, Junichi Soh1, Hiromasa Yamamoto1, Masashi 
Furukawa1, Eiki Ichihara2, Masaomi Yamane1, Takahiro Oto1, Katsuyuki Kiura2, 
Shinichiro Miyoshi1  
1Department Of Thoracic Surgery, Okayama University Graduate School Of Medicine, 
Dentistry And Pharmaceutical Sciences, Okayama/JAPAN, 2Department Of Hematology, 
Oncology And Respiratory Medicine, Okayama University Graduate School Of Medicine, 
Dentistry And Pharmaceutical Sciences, Okayama/JAPAN
Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) 
show remarkable response to drug sensitive EGFR-mutant lung cancer. However, acquired 
resistance to EGFR-TKIs is a critical problem in the treatment of lung cancer. While 
several mechanisms have been demonstrated to be responsible for acquired resistance, all 
mechanisms have not been uncovered. The purpose of this study was to indentify novel 
property of the acquired resistance and to explore the possibility of therapeutic strategy 
for acquired EGFR-TKI resistant lung cancer. Methods: EGFR mutant cell lines, HCC827 
(exon 19 deletion), PC-9 (exon 19 deletion), HCC4006 (exon 19 deletion), and HCC4011 
(L858R point mutation), were exposed to gefitinib with two different manners, stepwise 
escalation and high concentration exposure methods, and resistant cells to gefitinib were 
established. The molecular profiles, cellular phenotypes, and sensitivity to various drugs 
of established resistant cells were characterized. Results: With the stepwise escalation 
method, MET amplification was found in HCC827 and HCC4011 derived resistant 
sublines (HCC827-GRS and HCC4011-GRS) and T790M mutation was found in the PC-9 
derived subline (PC-9-GRS). Epithelial-to-mesenchymal transition (EMT) was observed 
in HCC4006 derived subline (HCC4006-GRS). With high concentration method, EMT 
was observed in HCC827 and HCC4006 derived sublines (HCC827-GRH and HCC4006-
GRH). MET amplification was found in HCC4011 derived subline (HCC4011-GRH). 
No specific molecular alteration was indentified in PC-9 derived subline (PC-9-GRH). 
Establishment of resistant cells with two different methods was performed twice or 
more to confirm reproducibility. Next, we investigated the detail of cellular properties of 
resistant sublines using mainly HCC827 and PC-9 derived cells. Of particular interest, 
we found stem-cell like properties including up-regulation of aldehyde dehydrogenase 
isoform 1 expression, sphere formation capability, and increased rate of side population 
using Hoechst 33342 staining only in HCC827-GRH not in other resistant sublines 
such as HCC827-GRS and PC-9 derivatives. In addition, multidrug resistance protein 1 
protein was also up-regulated in HCC827-GRH and acquired high degree of resistance to 
taxanes compared to their parental cells. On the other hand, the cyclopamine which was 
an antagonist of Smoothened protein, an important component of Hedgehog pathway, 
showed inhibition of cell viability in HCC827-GRH compared with in parental HCC827. 
Conclusion: Our study indicates that cellular environment in acquiring resistance to 
EGFR-TKI influences molecular and cellular features of resistant cells. As a novel feature 
of acquired resistant cells, we identify the stem-cell like property which can be is a 
therapeutic target of overcoming resistance.
Keywords: EGFR mutation, Tyrosine kinase inhibitor, acquired resistance, non-small cell 
lung cancer
